29 results found.

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial.
fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using IPI-145; Ofatumumab

Infinity Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO).
IPI-145; Ofatumumab

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using IPI-145; Ofatumumab

Infinity Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07.
IPI-145; Ofatumumab

Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymph Clinical Trial using Idelalisib

Gilead Sciences - Recruiting 18 years or older.
- Single-agent CAL-101 for Previously Teated Low-grade Lymphoma: A Phase 1/2 Study of Safety, Efficacy, and Flow-cytometric Assessment of Tumor-cell Signaling Events.
Idelalisib

Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Clinical Trial

Cancer Centre of Monoclonal Therapy, LLC - Recruiting 18 years or older.
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors.

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using ACP-196

Acerta Pharma BV - Recruiting 18 years or older.
- A Phase 1, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia.
ACP-196

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using PCI-32765 (Ibrutinib)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study.
PCI-32765 (Ibrutinib)

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 68 years.
- Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia.
Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

Monoclonal B-Cell Lymphocytosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers..

Small Lymphocytic Lymphoma, or CLL (Chronic Lymphocytic Leukemia) Clinical Trial using Fludarabine Phosphate; Ofatumumab; Cyclophosphamide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Fludarabine Phosphate; Ofatumumab; Cyclophosphamide

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using High Dose Methylprednisolone (HDMP); Ofatumumab; Lenalidomide

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial.
High Dose Methylprednisolone (HDMP); Ofatumumab; Lenalidomide

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL, or Clinical Trial using A6

ngstrom Pharmaceuticals - Recruiting 18 years or older.
- A Phase 2 Trial to Determine the Safety, Tolerability, and Efficacy of A6, a CD44 Binding Peptide, for the Treatment of Patients With Chronic Lymphocytic Leukemia.
A6

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL.
ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

Leukemia, or Lymphoma Clinical Trial using Rituximab; Lenalidomide

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy.
Rituximab; Lenalidomide

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using Ibrutinib; Bendamustine hydrochloride; Rituximab; Placebo

Janssen Research & Development, LLC - Recruiting 18 years or older.
- Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Ibrutinib; Bendamustine hydrochloride; Rituximab; Placebo

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using PCI-32765

Pharmacyclics - Recruiting 65 years or older.
- An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil).
PCI-32765

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma, o Clinical Trial using auranofin

University of Kansas - Recruiting 18 years or older.
- A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL).
auranofin

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymph Clinical Trial using bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years to 70 years.
- A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.
bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Leukemia, Leukemia, Lymphocytyc, CLL (Chronic Lymphocytic Leukemi Clinical Trial using PCI 32765

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion.
PCI 32765

B-Cell Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocyto Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Sta Clinical Trial using MOR00208; lenalidomide; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years to 80 years.
- A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)Prolymphocytic Leukemia (PLL) or Patients With Untreated CLL/SLL/PLL.
MOR00208; lenalidomide; Correlative Studies

Chronic Lymphocytic Leukemia (CLL), or Small Lymphocytic Lymphoma Clinical Trial using Idelalisib; Rituximab

Gilead Sciences - Recruiting 65 years or older.
- A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of Idelalisib Alone and in Combination With Rituximab in Elderly Subjects With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Idelalisib; Rituximab

Small Lymphocytic Lymphoma, or Chronic Lymphocytic Leukemia Clinical Trial using ABT-199; Rituximab

AbbVie - Recruiting 18 years or older.
- A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
ABT-199; Rituximab

Chronic Lymphocytic Leukemia (CLL), or Small Lymphocytic Lymphoma Clinical Trial using Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance

University of Wisconsin, Madison - Recruiting 18 years or older.
- HO11415: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxanr) and Lenalidomide (Revlimidr) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance

Leukemia Clinical Trial using Cyclophosphamide; Rituximab; Sapacitabine

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH.
Cyclophosphamide; Rituximab; Sapacitabine

Leukemia Lymphocytic Chronic B-Cell Clinical Trial using CC-292; Lenalidomide

Celgene Corporation - Recruiting 18 years or older.
- A Multicenter, Phase 1B, Open-Label Study to Determine the Safety and Activity of CC-292 in Combination With Lenalidomide in Subjects With Relapsed and /or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
CC-292; Lenalidomide

B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cance Clinical Trial using carfilzomib; Cytokine Assessment; Pharmacodynamic Studies; Proteosome Inhibition Assessment; Pharmacogenomic Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL).
carfilzomib; Cytokine Assessment; Pharmacodynamic Studies; Proteosome Inhibition Assessment; Pharmacogenomic Studies

Leukemia, or Lymphoma Clinical Trial using anti-thymocyte globulin; rituximab; busulfan; cyclophosphamide; fludarabine phosphate; methotrexate; sirolimus; tacrolimus; laboratory biomarker analysis; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 18 years to 69 years.
- Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL).
anti-thymocyte globulin; rituximab; busulfan; cyclophosphamide; fludarabine phosphate; methotrexate; sirolimus; tacrolimus; laboratory biomarker analysis; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation

Leukemia Clinical Trial using Immunotoxin therapy; CAT-8015 immunotoxin; Biological therapy

Cambridge Antibody Technology - Recruiting 18 years or older.
- A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia (CLL), Prolymphocytic Leukemia (PLL), or Small Lymphocytic Lymphoma (SLL).
Immunotoxin therapy; CAT-8015 immunotoxin; Biological therapy